2017 Gene Replikin Counts in Global MERS-CoV Increase Four-Fold Over 2008 Count

BOSTON, Dec. 7, 2017 /PRNewswire/ -- Replikins Ltd. this week reported to the Healthcare Emergency Management Program of Boston University School of Medicine a four-fold increase in gene Replikin Counts in Global MERS-CoV from 2008 to 2017 (p<0.001) – the highest ever recorded on Pubmed for MERS-CoV (See Figure below).

The dramatic increase in gene Replikin Count (number of Replikins per 100 amino acids) serves as a predictor of severe outbreaks of a "new" mutated MERS-CoV, and should be compared with the same phenomenon reported for influenza H1N1 in 2008 predicting the 2009 pandemic, of H3N2 for several years 2004-2017, for Zika virus in 2015 and February 2017, and for Influenza H5N8 in November 2017.  

The increases also are accompanied by a marked increase in mutation rate. The resultant substitution of the MERS-CoV antigenic base increases the risk that vaccines and blockers based on virus structures before 2017 will be less effective against the MERS-CoV antigenic base currently in circulation.

With over three million Replikins automated analyses of 18 virus genes, one to four years advance notice of the outbreaks consistently provide time for both public health preparations and the synthesis and testing of blockers and vaccines, overcoming the organism's advantage of surprise. 

The prediction one year in advance of the H1N1 2009 Pandemic, and 6 months in advance of the sudden unexpected cessation of the 2014 Ebola outbreak, as well as the other consistent advance information of outbreaks and cessations over 10 years, has led to the formation of the Replikins SurveillanceService™.  The Gates Foundation and the World Bank have recently urged more efforts and new efforts in advance of the outbreak.

Because, to our knowledge, it is the only source of reliable automated quantitative advance information on infectious disease outbreak and cessation, the Replikins SurveillanceService™ uniquely can offer the solid phase synthesis in seven days of up-to-date Replikin blockers and vaccines against the markedly mutated MERS-CoV currently in circulation, and against mutations in other viruses and bacteria.

The Service also offers the particular expertise of those Service subscribers including the Boston University School of Medicine Healthcare Emergency Management Program, which, in addition to the basic subscription to receive advance information, wish to work with other Service subscribers and Replikins,Ltd. in the effort to ameliorate and eventually prevent infectious disease outbreaks and pandemics.

For further information and subscription to
Replikins SurveillanceService™, contact:

Samuel Bogoch, MD,PhD.
[email protected] 
tel.646-320-5910

copyright Replikins,Ltd. 2017

SOURCE Replikins Ltd.